La cadena de opciones muestra datos clave de las opciones de acciones de Recursion Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Recursion Pharmaceuticals..

Recursion Pharmaceuticals (NASDAQ:RXRX) Bolsa, Cadena de Opciones

RECURSION PHARMACEUTICALS-A

Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

APPS

AVGR

BBAI

COHR

DGLY

FORM

MBRX

MTRX

PTIX

RANI

RXRX

SBET

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SLXN

SWKS

Coherent sorprende con sus resultados trimestrales y dispara sus acciones un 15,5%. ¿Qué otras empresas se mueven en el premercado de EE.UU.?

Acciones de Coherent (COHR) se disparan un 15%; 20 acciones que se mueven en el premercado de EE.UU.

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals Inc

Press Releases

Recursion to Participate in Upcoming Investor Conferences

Small Cap

AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names

General

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Opinion

AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway

Doctors Are Being Outpaced by AI-Powered Algorithms -- Here's What It Means for Investors

Health Care

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Earnings

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

ASTH

AVAI

BFLY

MDAI

MSFT

OABI

ORCL

RLYB

TREN

TVGN

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

Cidara Therapeutics

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

89bio

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

GRAIL

ImmunityBio

IDEAYA Biosciences

Immunovant

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mesoblast Limited - American Depositary Shares

Mesoblast

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Veracyte

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals

Needham

Morgan Stanley

Leerink Partners

Keybanc

Jefferies

Screenshot 2025-09-08 at 3.59.27 PM

Biotech

BDRX

Tempest Therapeutics, Inc. - Common Stock

TPST

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patient Enrolled

BDRX-logo

PVLA

How Biodexa Is Racing To Get Its Phase 3 Program In FAP Under Way And Gain First-Mover Advantage In A $7B Addressable Market

Comments

Recursion Pharmaceuticals

Recursion Pharmaceuticals (RXRX) Opciones

Recursion Pharmaceuticals (NASDAQ:RXRX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL